Effect of ofatumumab versus placebo in relapsing multiple sclerosis patients from Japan and Russia: Phase 2 APOLITOS study
Authors:
- 17 November 2021
- journal article
- research article
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 28 (8) , 1229-1238
Abstract
Background: Ofatumumab, the first fully human anti-CD20 monoclonal antibody, has been developed as a treatment for relapsing multiple sclerosis (RMS) which can be self-administered at home. Objective: To investigate the efficacy and safety of ofatumumab in RMS patients from Japan and Russia. Methods: APOLITOS included a 24-week, double-blind, placebo-controlled core-part followed by an open-label extension-part. Patients were randomized (2:1) to subcutaneous ofatumumab 20 mg or placebo. Primary outcome was the number of gadolinium-enhancing (Gd+) T1 lesions per scan over 24 weeks. Results: Sixty-four patients were randomized (ofatumumab, n = 43; placebo, n = 21). Primary endpoint was met; ofatumumab reduced Gd + T1 lesions versus placebo by 93.6% ( p < 0.001) and the results were consistent across regions (Japan/Russia). Ofatumumab reduced annualized T2 lesion and relapse rate versus placebo by week 24. Both groups showed benefit from ofatumumab in the extension-part. Incidence of adverse events was lower with ofatumumab versus placebo (69.8% vs 81.0%); injection-related reactions were most common. No deaths, opportunistic infections, or malignancies were reported. Conclusion: Ofatumumab demonstrated superior efficacy versus placebo, with sustained effect through 48 weeks in RMS patients from Japan/Russia. Switching to ofatumumab after 24 weeks led to rapid radiological and clinical benefits. Safety findings were consistent with pivotal trials.Keywords
Funding Information
- Novartis Pharma
This publication has 7 references indexed in Scilit:
- Ofatumumab versus Teriflunomide in Multiple SclerosisNew England Journal of Medicine, 2020
- Anti-CD20 Antibodies Ofatumumab and Ocrelizumab Have Distinct Effects on Human B-cell Survival (S52.003)Neurology, 2018
- Prevalence, treatments and medical cost of multiple sclerosis in Japan based on analysis of a health insurance claims databaseClinical and Experimental Neuroimmunology, 2017
- Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional propertiesmAbs, 2013
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteriaAnnals of Neurology, 2011
- Declaration of Helsinki. Ethical Principles for Medical Research Involving Human SubjectsJahrbuch für Wissenschaft und Ethik, 2009
- Rating neurologic impairment in multiple sclerosisNeurology, 1983